CRISPR Therapeutics Outlines 2026 Strategy and Milestones with $2 Billion Cash Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Newsfilter
- Strong Financial Foundation: CRISPR Therapeutics starts 2026 with approximately $2 billion in cash and cash equivalents, providing robust financial support for ongoing R&D and market expansion, thereby enhancing investor confidence.
- Global Promotion of CASGEVY®: With approvals in the U.S., EU, and other regions, CASGEVY generated over $100 million in revenue in 2025, and its continued commercialization in 2026 is expected to solidify the company's leadership in gene therapy.
- Clinical Trial Progress: The company plans to initiate regulatory submissions for CASGEVY in patients aged 5-11 in the first half of 2026, while top-line Phase 2 data for CTX611 is anticipated in the second half, providing critical data support for further development in cardiovascular and immuno-oncology sectors.
- Diverse Product Pipeline: CRISPR Therapeutics is advancing multiple clinical and preclinical projects, including CTX310 for severe hypertriglyceridemia and zugo-cel for autoimmune diseases, showcasing its broad application potential across various therapeutic areas.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 53.840
Low
40.00
Averages
73.41
High
105.00
Current: 53.840
Low
40.00
Averages
73.41
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
